Administering the pan-PHD inhibitor DMOG in advanced stages of tumor development resulted in a significantly increased relative liver weight, a slight decrease in HCC and a minor increase in cholangioma lesions coinciding with a significantly increased expression of LPC markers and number of CK19+ single cells. Here, KRT19 is linked to bile duct adenoma.